仙琚制药子公司获高新认定 募投项目延期至2026年底

Group 1 - The core viewpoint of the news is that Xianju Pharmaceutical's subsidiary, Taizhou Xianju Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, allowing it to enjoy a 15% corporate income tax rate for three consecutive years from 2025 to 2027 [1] Group 2 - The company's project, "High-end Formulation Internationalization Construction Project," has been delayed from its original completion date of the end of 2025 to December 31, 2026. As of October 31, 2025, the project has invested 636 million yuan, achieving a progress rate of 90.79%. The delay is primarily due to the incomplete approval processes for certain products [2]